Omecamtiv mecarbil

Drug Profile

Omecamtiv mecarbil

Alternative Names: AMG-423; CK-1827452; CK-452

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Cytokinetics
  • Developer Amgen; Cytokinetics
  • Class Esters; Heart failure therapies; Organic chemicals; Piperazines; Pyridines; Small molecules
  • Mechanism of Action Cardiac myosin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic heart failure
  • Phase II Acute heart failure; Heart failure
  • No development reported Angina pectoris; Cardiomyopathies

Most Recent Events

  • 01 Dec 2016 Phase-III clinical trials in Chronic heart failure in USA (PO) (NCT02929329)
  • 14 Nov 2016 Additional efficacy data from the phase II COSMIC-HF trial in Chronic heart failure released by Cytokinetics
  • 18 Oct 2016 Amgen plans the phase III GALACTIC-HF trial for Heart failure in USA and European Union (PO) (NCT02929329)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top